New treatments for metabolic diseases in cystic fibrosis patients
Official title: Novel Selective SGLT-1 Inhibitors for Adjunctive Therapy for Cystic Fibrosis Associated Metabolic Diseases
Funded at Genetobe INC. · NIH-11006091 · Data updated 2026-11-12
This study is looking at new medications that could help people with cystic fibrosis manage diabetes and liver issues by targeting specific glucose transporters, especially for those who have had worsening health after starting a treatment called Trikafta.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Genetobe INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 10, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,779 |
| NIH project number | 1R42DK141338-01 |
| Project ID | NIH-11006091 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cystic fibrosis who are experiencing metabolic complications, particularly those related to diabetes and liver disease.
✕Less likely to help
Patients without cystic fibrosis or those who do not have metabolic complications associated with the disease may not benefit from this research.
What this research studies
This research focuses on developing new medications that target specific glucose transporters to help manage metabolic diseases associated with cystic fibrosis, particularly CF-related diabetes and liver disease. The approach involves creating selective inhibitors of the sodium-dependent glucose cotransporter 1 (SGLT1), which may help improve metabolic health in patients who have experienced worsening conditions after starting Trikafta, a recently approved cystic fibrosis treatment. The research utilizes a novel rabbit model that mimics the metabolic disorders seen in cystic fibrosis patients, allowing for targeted testing of these new compounds.
Why it matters
Potential benefit: If successful, this research could lead to improved management of metabolic diseases in cystic fibrosis patients, enhancing their overall health and quality of life.
How similar studies have gone: While the approach of targeting SGLT1 is relatively novel, there have been successes with other SGLT inhibitors in treating diabetes, suggesting potential for this new line of therapy.
Where this research is happening
-
Genetobe INC.
Ann Arbor, United States Active
Researchers
- Principal investigator: Xu, Jie — Genetobe INC.
- Study coordinator: Xu, Jie
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.